Research Paper
A novel cuproptosis-associated immune risk model for prediction of prognosis and response to immunotherapy in triple-negative breast cancer
Figure 9. Upregulated expression of IDO1 and THY1 in TNBC cell lines and tissue samples. (A) Significantly different expression of the IDO1 among breast cancer tissues and normal tissues. (B) qRT-PCR examined the mRNA expression of IDO1 gene in MCF-10A, MDA-MB-231, and MDA-MB-468 cell lines. (C) Significantly different expression of the THY1 gene between breast cancer tissues and normal tissues. (D) qRT-PCR examined the mRNA expression of THY1 gene in MCF-10A, MDA-MB-231, and MDA-MB-468 cell lines. (E, F) IHC staining of IDO1 and THY1 protein in adjacent normal tissues and TNBC tissues. (*P<0.05, **P< 0.01, ***P< 0.001).